Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Agilent, Sigma-Aldrich, Bruker Biosciences, Thermo Fisher Scientific, CombiMatrix

Beckman Coulter Selling $600M Worth of Senior Notes
 
Beckman Coulter this week said that it is offering $600 million worth of 2.5 percent senior convertible notes due 2036.
 
The offering, which includes a $75 million over-allotment option that has already been exercised, will net Beckman proceeds of $586 million.
 
The firm said it would use roughly $100 million of the proceeds to repurchase shares of its common stock. In a separate announcement this week, Beckman had said its board of directors had approved the repurchase of up to 2.5 million shares of its outstanding common stock through the end of 2008.
 
Beckman said that approximately $245 million of the proceeds from the senior notes offering would be used to consummate a tender offer for all of its outstanding 7.45 percent senior notes due 2008. It plans to use approximately $185 million of the proceeds to repay the bridge facility that it entered in connection with its recent acquisition of Lumigen.
 
According to Beckman, the purpose of the offering is to reduce its interest expense in order to fund additional research and development efforts, including the development of a next-generation molecular diagnostics platform (see related article).
 

 
Agilent Confirms Q1 Forecast
 
Agilent Technologies this week confirmed its first-quarter revenue guidance of $1.25 billion to $1.29 billion, which would be growth of between 7 percent and 10 percent year over year.
 
In a presentation to analysts and investors, the firm also confirmed its earlier guidance of earnings per share of $.36 to $.40 for the quarter ending Jan. 31, 2007, which is 24 percent to 38 percent above last year’s first quarter results. Analysts polled by Thomson Financial expect the firm to post a profit of $.38 per share and revenue of $1.27 billion.
 
Additionally, Agilent said that it is “comfortable with the current range of analysts’ estimates” for its 2007 fiscal year ending Oct. 31, 2007.
 

 
Sigma-Aldrich Closes Debt Offering, Amends Credit Facility
 
Sigma-Aldrich last week closed a $100 million debt offering of 5.11-percent senior notes due Dec. 5, 2011.
 
The notes were placed with an unnamed institutional investor.
 
The company also said it retired $75 million 5.16 percent senior notes that matured on Nov. 20.
 
In a separate announcement this week, the firm said that it had amended the terms of its $150 million revolving credit facility established in Feb. 2005 by exercising the $150-million accordion feature. The revised $300 million revolving credit facility will mature on Dec. 11, 2011.
 

 
Bruker to Open Bruker AXS Unit in Australia
 
Bruker Biosciences this week said that it will launch a new Bruker AXS business unit in Melbourne, Australia, on Jan. 1, 2007.
 
The unit, which makes X-ray analysis tools for the industrial, materials research, and life sciences industries, will be responsible for selling products formerly distributed by Australian partner Sietronics. Bruker said that in an effort to ensure continuity, it has secured business management and service resources from its former distributor.
 

 
Brazilian Firm to Distribute Thermo Fisher’s LIMS System
 
Thermo Fisher Scientific last week said Brazilian company Interfusão will distribute and deploy Thermo’s SampleManager LIMS system and chromatography data systems to mining, metals, and minerals companies.
 
Financial terms of the agreement were not released.  
 

 
CombiMatrix to Gain $10M from Acacia Investors
 
CombiMatrix last week said it stands to pocket $10 million when its parent company Acacia Research received commitments from “a select group of investors” to buy 9.8 million units of equity for $1.02 each.
 
Each unit includes one Acacia Research-CombiMatrix share and a five-year warrant to buy 1.2 million shares at $.87 each. The placement was handled by Oppenheimer & Co.
 
In an interview with BioCommerce Week’s sister publication BioArray News this week, CombiMatrix CEO Amit Kumar said the firm will use the VC cash to support the launch of several diagnostics services through its CombiMatrix Molecular Diagnostics unit.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more